Aktienbewertung
Konkurrenz
| Unternehmen | Börsenwert | G | R | O | W | T | H |
|---|---|---|---|---|---|---|---|
|
Eli Lilly and NYSE:LLY |
725,47 Mrd. $ | 15,90 % | 6/6 | 51,27 % | -22,41 % | 20,34 % | UP |
|
Novartis SWX:NOVN |
180,69 Mrd. CHF | 3,98 % | 6/6 | -1,86 % | -2,38 % | 2,89 % | DOWN |
|
GSK LSE:GSK |
56,44 Mrd. £ | -0,73 % | 3/6 | 2,20 % | 16,80 % | 8,01 % | DOWN |
|
Takeda Pharmaceutical Company TSE:4502 |
6.798,06 Mrd. ¥ | 45,85 % | 4/6 | 31,00 % | -12,86 % | 13,94 % | UP |
|
Daiichi Sankyo Company TSE:4568 |
6.817,07 Mrd. ¥ | 14,99 % | 4/6 | 27,55 % | 50,16 % | 55,74 % | DOWN |
|
Supernus Pharmaceuticals NasdaqGM:SUPN |
2,09 Mrd. $ | 7,03 % | 3/6 | -16,33 % | -3,09 % | 13,74 % | UP |
|
BioCryst Pharmaceuticals NasdaqGS:BCRX |
1,73 Mrd. $ | 56,16 % | 5/6 | -1,06 % | 41,78 % | 93,70 % | UP |
